Extensive limb swelling after immunization: Reports to the vaccine adverse event reporting system

被引:54
作者
Woo, EJ [1 ]
Burwen, DR [1 ]
Gatumu, SNM [1 ]
Ball, R [1 ]
机构
[1] US FDA, Vaccine Safety Branch, Div Epidemiol, Off Biostat & Epidemiol,Ctr Biol Evaluat & Res, Rockville, MD 20852 USA
关键词
D O I
10.1086/375820
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Extensive limb swelling (ELS) has been reported after vaccination with a limited number of vaccine types. We sought to describe vaccine types involved in and the clinical characteristics of ELS cases reported to the Vaccine Adverse Event Reporting System (VAERS). A case of ELS was defined as any report of edema extending at least to the elbow or knee of a vaccinated extremity. Four hundred ninety-seven cases were identified, with some describing swelling from the shoulder to the hand or the hip to the foot. Patient age ranged from 0.1 to 91 years. The proportion of reports of ELS associated with a given vaccine, among all VAERS reports received for that vaccine, varied substantially among vaccines. Most reactions began within 1 day after vaccination and involved other signs of inflammation. Postvaccination ELS can involve both the proximal and distal segments of the extremity, affects all age groups, and occurs after vaccination with a broad range of vaccines.
引用
收藏
页码:351 / 358
页数:8
相关论文
共 20 条
[1]  
[Anonymous], MMWR MORB MORTAL WKL
[2]   Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2, 4 and 6 month old infants in the United States [J].
Bernstein, HH ;
Rothstein, EP ;
Pichichero, ME ;
Green, JL ;
Reisinger, KS ;
Blatter, MM ;
Halpern, J ;
Arbeter, AM ;
Bernstein, DI ;
Smith, V ;
Long, SS ;
Rathfon, H ;
Krause, DS .
VACCINE, 1995, 13 (17) :1631-1635
[3]   FIELD-EVALUATION OF A HUMAN ANTHRAX VACCINE [J].
BRACHMAN, PS ;
FEKETY, FR ;
GOLD, H ;
WERRIN, M ;
INGRAHAM, NR ;
PLOTKIN, SA .
AMERICAN JOURNAL OF PUBLIC HEALTH AND THE NATIONS HEALTH, 1962, 52 (04) :632-+
[4]   THE VACCINE-ADVERSE-EVENT-REPORTING-SYSTEM (VAERS) [J].
CHEN, RT ;
RASTOGI, SC ;
MULLEN, JR ;
HAYES, SW ;
COCHI, SL ;
DONLON, JA ;
WASSILAK, SG .
VACCINE, 1994, 12 (06) :542-550
[5]  
degli Atti MLC, 2001, VACCINE, V20, P989
[6]   Monitoring the safety of vaccines - Assessing the risks [J].
Ellenberg, SS ;
Braun, MM .
DRUG SAFETY, 2002, 25 (03) :145-152
[7]  
FDA U.S, 2001, ADV NOT PROP RUL CON, V66
[8]   Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life [J].
Halperin, SA ;
Eastwood, BJ ;
Barreto, L ;
Friesen, B ;
Medd, L ;
Meekison, W ;
Guasparini, R .
VACCINE, 1996, 14 (08) :767-772
[9]   Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids [J].
Jackson, LA ;
Carste, BA ;
Malais, D ;
Froeschle, J .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (08) :781-786
[10]   IMMUNOGENICITY AND REACTOGENICITY OF TAKEDA ACELLULAR PERTUSSIS-COMPONENT DIPHTHERIA-TETANUS-PERTUSSIS VACCINE IN 2-MONTH-OLD AND 3-MONTH-OLD CHILDREN IN JAPAN [J].
KAMIYA, H ;
NII, R ;
MATSUDA, T ;
YASUDA, N ;
CHRISTENSON, PD ;
CHERRY, JD .
AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1992, 146 (10) :1141-1147